Cathie Wood's weekly recap: ramps up bets on JOBY, CRSP, pares ILMN, VCYT

Cathie Wood's weekly recap: ramps up bets on JOBY, CRSP, pares ILMN, VCYT
Standard BioTools jumps on sale of SomaLogic to Illumina
Illumina wins legal battle over Grail deal in EU; avoids €432M fine
Illumina gains as adviser to EU top court backs appeal over Grail deal
Activist Icahn drops threat to start another proxy battle with Illumina - Reuters
19.43BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US4523271090
CUSIP
452327109
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
23.58
PEG Ratio
2.33
Book Value
17.80
Dividend Share
-
Dividend Yield
-
Earnings Share
5.45
Wall Street Target Price
136.67
EPS Estimate Current Year
5.12
EPS Estimate Next Year
5.82
EPS Estimate Current Quarter
1.2307
EPS Estimate Next Quarter
1.1343
Most Recent Quarter
-
Revenue TTM
4,343,000,064
Gross Profit TTM
2,964,000,000
EBITDA
1,139,000,064
Profit Margin
19.57%
Return On Assets TTM
8.39%
Return On Equity TTM
33.36%
Revenue Per Share TTM
28.019
Qtly Revenue Growth YOY
5.00%
Diluted Eps TTM
5.45
Qtly Earnings Growth YOY
86.40%
Trailing PE
23.58
Forward PE
24
Price Sales TTM
4.4953
Price Book MRQ
7.134
Enterprise Value Revenue
4
Enterprise Value EBITDA
13
18.12
12.55%472.18
0.87%300.73
0.31%158.98
-3.01%61.12
-1.80%201.22
-1.50%567.85
-1.27%617.40
-1.23%179.05
-0.86%114.87
-0.66%Curated watchlists where ILMN is featured.